Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Income from Continuing Operations (2020 - 2025)

Ovid Therapeutics' Income from Continuing Operations history spans 6 years, with the latest figure at 9663000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 204.43% year-over-year to 9663000.0; the TTM value through Dec 2025 reached 17414000.0, up 34.12%, while the annual FY2025 figure was 17414000.0, 34.12% up from the prior year.
  • Income from Continuing Operations reached 9663000.0 in Q4 2025 per OVID's latest filing, up from 12158000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 176007307.0 in Q1 2021 to a low of 26000048.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 1375972.3, with a median of 11830885.5 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: surged 978.71% in 2021, then crashed 154.97% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 26000048.0 in 2021, then surged by 55.75% to 11504789.0 in 2022, then tumbled by 33.18% to 15322000.0 in 2023, then surged by 39.61% to 9253000.0 in 2024, then surged by 204.43% to 9663000.0 in 2025.
  • Per Business Quant, the three most recent readings for OVID's Income from Continuing Operations are 9663000.0 (Q4 2025), 12158000.0 (Q3 2025), and 4684000.0 (Q2 2025).